Vandoeuvre Les Nancy

• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Ra … Ended recruitment
  2022-502269-13-00 4 2024-09-24 Glioma
• A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastat … Ended recruitment
  2023-505655-43-00 7 2024-07-29 Metastatic neuroendocrine prostate cancer
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• An Open-label Dosimetry, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients with Progressive PSMA-Positive … Ended recruitment
  2023-503925-20-00 4 2024-04-04 Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Can
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended recruitment
  2023-506988-34-00 5 2024-03-27 Heart failure with mildly reduced or preserved ejection fraction and s
• FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatme … Ended recruitment
  2022-501372-25-00 4 2024-01-10 Patients aged 18 years and older with relapsed or refractory FLT3 muta
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran … Ended recruitment
  2024-514876-41-00 9 2023-12-06 Higher-risk myelodysplastic syndromes untreated and ineligible for all
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended recruitment
  2023-503952-28-00 4 2023-11-13 Steroid refractory Acute Graft versus host Disease
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH … Ended recruitment
  2023-507672-52-00 7 2023-11-07 PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and
• A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He … Ended recruitment
  2023-503422-39-00 5 2023-10-20 Hepatocellular Carcinoma (HCC)
• 1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended recruitment
  2022-500430-29-00 5 2023-10-11 Myelodysplastic Syndrome (MDS)
• A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended recruitment
  2022-500953-17-00 4 2023-03-23 Moderately to severely active ulcerative colitis
• A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen … Ended recruitment
  2024-512890-28-00 5 2023-03-20 Primary immune thrombocytopenia (ITP)
• A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely … Ended recruitment
  2023-504719-34-00 5 2023-02-21 Moderate to Severly Active Ulcerative Colitis
• A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie … Ended recruitment
  2022-501493-19-00 5 2023-02-20 metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Evaluating the superiority of VAsopressin versus NOradrenaline in the management of the renal risk patient undergoing cardiac surgery with e … Ended recruitment
  2022-500419-38-00 5 2022-12-28 vasoplegic syndrome
• Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-N … Ended recruitment
  2024-515845-40-00 5 2022-11-22 Acute kidney injury
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N … Ended recruitment
  2024-510947-71-00 5 2022-11-21 Chronic Myeloid Leukemia
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n … Ended recruitment
  2023-508559-37-00 5 2022-07-14 Lupus nephritis
• Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and … Ended recruitment
  2024-516403-16-00 5 2022-04-07 Adult patients with immune thrombocytopenia (ITP) with mild to severe
• PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION ( … Ended recruitment
  2024-515037-15-00 4 2022-03-02 PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATI

Showing 169–192 of 274 trials